Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective

INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Borse, Rebekah H., Brown, Chloe, Muszbek, Noemi, Chaudhary, Mohammad Ashraf, Kachroo, Sumesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696295/
https://www.ncbi.nlm.nih.gov/pubmed/28956301
http://dx.doi.org/10.1007/s40744-017-0083-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696295/
https://www.ncbi.nlm.nih.gov/pubmed/28956301
http://dx.doi.org/10.1007/s40744-017-0083-1

Ejemplares similares